When Drug Pricing Policy Starts to Shape Where Medicines Are Made

For years, European pharmaceutical companies have treated manufacturing location as an operational decision. That is changing.

Ipsen is reportedly considering a U.S. manufacturing site while continuing to expand production in the United Kingdom. The company has not made a final decision, but the question itself reflects a broader shift facing European drugmakers. The Wall Street Journal, September 11, 2026

A company deciding where to manufacture a medicine now has to consider more than labor, capacity and logistics. It must also think about tariffs, domestic-production incentives, political pressure, reimbursement rules and the order in which products should be launched in different markets.

A U.S. facility may help a company respond to trade demands or qualify for incentives. It may also bring higher construction and operating costs. Building in Europe may preserve existing expertise and infrastructure, while exposing the company to a different set of political and commercial risks.

The decision becomes even more complicated when a product is approaching launch. A company may have to determine whether the economics justify a new facility, a contract manufacturing arrangement, an acquisition or an expansion of an existing site. Each option affects capital allocation, regulatory planning and the timing of market entry.

This is not only a question for the largest pharmaceutical companies. Smaller biotechs and specialty manufacturers may face the same choice earlier in their development cycle because investors and strategic partners want to know where production will occur and how resilient the supply chain will be.

The larger point is that drug pricing policy is beginning to influence industrial policy. Decisions about reimbursement and market access can affect where companies build, where they hire and where they place their next dollar of investment.

For European life-sciences companies looking toward the United States, manufacturing strategy can no longer be separated from policy strategy.